OV-90 Cells

OV-90 is a human epithelial ovarian cancer (EOC) cell line derived from malignant ascites of an adult patient who had not received prior chemotherapy or radiation treatment. It belongs to a panel of spontaneously immortalized ovarian cancer cell lines that were developed to preserve key clinical and molecular features of the tumors from which they originated. OV-90, in particular, exhibits aggressive in vitro growth behavior that correlates with its clinical derivation from a patient with advanced disease. Cytogenetically, OV-90 cells carry mutations in tumor suppressor genes and oncogenes frequently implicated in ovarian cancer, including TP53 and BRCA2, as well as alterations in TGF-β receptor type II and CDKN2A. These mutations reflect the genomic instability commonly observed in high-grade serous ovarian carcinomas.

Gene expression profiling of OV-90 reveals a distinct molecular signature consistent with its tumor origin. Comparative microarray analyses have shown that OV-90’s transcriptomic profile diverges significantly from that of normal ovarian surface epithelium, with strong upregulation of genes involved in proliferation, DNA damage response, and invasion. Moreover, among the ovarian cancer lines studied, OV-90 clusters with other aggressive tumor-derived lines rather than with those derived from indolent disease, making it a useful model for investigating high-risk disease biology. Its expression patterns also align with clinical markers of poor prognosis, further supporting its utility in preclinical research focused on aggressive ovarian cancer subtypes.

In systems biology and pharmacogenomic studies, OV-90 has been included in large-scale transcriptomic and proteomic analyses, including the Cancer Cell Line Encyclopedia (CCLE) and proteomic atlases. These datasets reveal copy number alterations and gene expression changes that can be correlated with drug sensitivity, particularly to agents targeting DNA repair pathways or cell cycle regulators. The availability of this comprehensive multi-omic data, alongside OV-90’s phenotypic and genetic fidelity to aggressive ovarian carcinoma, underscores its value in drug development, biomarker discovery, and mechanistic studies of ovarian cancer pathogenesis.